| Literature DB >> 20055660 |
Taimur Sher1, Kena C Miller, David Lawrence, Amy Whitworth, Francisco Hernandez-Ilizaliturri, Myron S Czuczman, Austin Miller, William Lawrence, Syed Ali Bilgrami, Raman Sood, Margaret T Wood, Annemarie W Block, Kelvin Lee, Asher Alban Chanan-Khan.
Abstract
Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than demonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20055660 DOI： 10.3109/10428190903406806
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022